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Dear Editor 
 
The knowledge of lncRNAs in multiple myeloma (MM) is continuously increasing.1, 2 We and 
others have recently provided evidence by microarray3 or RNA sequencing (RNA-seq) analyses2, 4 
that distinct lncRNA transcriptional signatures distinguished myeloma cells from normal 
counterpart, were specifically associated with molecular subgroups or progressive disease phases, 
and could be independently related to MM clinical outcome.4 Among the most expressed lncRNAs, 
we identified the nuclear paraspeckle assembly transcript 1 (NEAT1),2 already reported to be 
overexpressed in many types of solid tumors, raising the hypothesis that it may play a critical 
oncogenic role and facilitate tumorigenesis.5 Herein, we demonstrated that MM cells significantly 
overexpress NEAT1 and its deregulation is unrelated to the patients’ prognosis. However, the 
putative NEAT1 involvement in cellular stress response makes it an attractive candidate for targeted 
therapy in the disease. 
The expression profile of NEAT1 has been primarily investigated by GeneChip® Human Gene 
2.0 ST array in a cohort of 50 MMs representative of the major molecular characteristics of the 
disease (Supplementary Table S1), in 9 primary plasma cell leukemia (pPCL) and 6 secondary PCL 
(sPCL), and in 4 purified bone marrow PCs from healthy controls (N). Almost 19000 coding genes 
and 10138 lncRNAs have been annotated based on the GENCODE encyclopedia as previously 
described.3 NEAT1 belonged to a short list of 17 lncRNAs markedly expressed in MM patients 
(Supplementary Table S2). NEAT1 presents two isoforms: a canonically polyadenylated short 
transcript of 3.7 kb (NEAT1_1) and a longer non-polyadenylated transcript (NEAT1_2) of about 23 
kb. The analysis indicated that NEAT1 showed significant overexpression in pathological MM and 
both pPCL and sPCL samples as compared with healthy donors (Figure 1A). Notably, MM patients 
overexpressed NEAT1 irrespectively of their molecular characteristic, i.e. the presence of 
chromosomal translocations, hyperdiploidy, 13q and 17p13 deletion, gain of 1q arm, mutations of 
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the MAPK-pathway (BRAF, NRAS, or KRAS), or FAM46C and DIS3 genes (Figure 1B and 
Supplementary Figure S1).  
Subsequently, we evaluated the expression of NEAT1 in 30 of the 50 MM patients for whom 
RNA-seq data were available2 (Figure 1C). RNA-seq allowed to estimate NEAT1_1 and NEAT1_2 
isoforms abundance based on the presence of unambiguously mapped reads. Importantly, we found 
that NEAT1_1 isoform was much more abundant than the longer NEAT1_2 isoform, being 
approximately 90% of total NEAT1 abundance (Figure 1D). The results on these 30 patients, 
representative of the major genetic/prognostic lesions, confirmed that NEAT1 is not differentially 
expressed in the diverse MM molecular subtypes.2 
NEAT1 expression levels were therefore validated by quantitative real-time PCR (qRT-PCR, 
Supplementary Table S3) in 60 (46 MM and 14 PCL) of the pathological samples examined by 
arrays and in 46 additional patients including 36 MM, 5 smoldering MM, 5 PCL. NEAT1 global 
expression levels were first obtained by targeting the 5’-region, to amplify both transcripts. The 
expression pattern observed was consistent with the array results (Supplementary Figure S2). 
Furthermore, we used a second primers configuration that targeted the 3’-region, to amplify 
exclusively the NEAT1_2 isoform. As such, we confirmed the estimated proportion of NEAT1_2 in 
the overall NEAT1 expression as shown by RNA-seq and proved that the long isoform NEAT1_2 
was positively correlated with total NEAT1 (Figure 1E). No differential expression was found in 
the small subset of smoldering MM (Supplementary Figure S3), in line with previous observations 
that indicated lack of significant differences in pathological specimens. Next, we validated these 
findings in two publicly available array-based datasets from the University of Arkansas for Medical 
Science (UAMS), including 22 healthy donors, 12 monoclonal gammopathy of undetermined 
significance (MGUS), 44 smoldering MM (#GSE5900 series on NCBI GEO repository) and the 
large array-profiled UAMS TT2/TT3 trials cohort encompassing more than 550 patients 
(#GSE2658 and #GSE24080). Underexpression of NEAT1 was confirmed in healthy donors; 
NEAT1 levels were also significantly reduced in MGUS patients compared to MM (Supplementary 
 4
Figure S4). However, for the sake of clarity, it is worth specifying that these datasets, given the 
related array configuration, investigated preferentially the short polyadenylated NEAT1_1 isoform. 
 To gain insights into the possible role of deregulated NEAT1 in MM, we investigated the 
protein-coding genes concurrently detected by Gene 2.0 ST array. NEAT1 is an indispensable 
structural component of paraspeckles (PSs), peculiar lncRNA-directed nuclear bodies potentially 
involved in stress response. Although their exact function has to be fully elucidated, PSs may affect 
gene expression by regulating the transcription and pre-mRNA splicing events and holding nuclear 
mRNA for editing. NEAT1 could control these events by modulating the functions of PSs upon 
exposure to specific stress events.6-8 Notably, in our cohort of sample NEAT1 expression is 
significantly correlated with that of NONO and SFPQ (Pearson correlation R>0.3, p<0.01, 
Supplementary Figure S5), both encoding for proteins essential to the formation of minimal 
ribonucleoprotein particles.9 These data suggest that NEAT1 overexpression in MM may be 
associated with increased PSs formation.   
With NEAT1 being expressed at high level in all tumor samples but presenting low variance 
across the whole dataset, we focused on those patients at the extremes of the expression distribution 
to unravel putative biological effects associated with its modulation. Namely, we compared the 
transcriptional profiles of patients showing the highest and the lowest quartile of NEAT1 expression 
levels, obtaining 138 differentially expressed genes (Supplementary Table S4). Functional 
annotation analysis of this signature, aimed at identifying highly significant represented categories, 
interestingly revealed enrichment in the unfolded protein response (UPR) category, which is the 
cellular response to the endoplasmic reticulum stress due to the accumulation of unfolded or 
misfolded proteins (Supplementary Table S5). Specifically, among the 7 genes included in this gene 
set (BAG3, EXOSC2, TUBB2A, DDX10, PREB, NFYA, GEMIN4), MM with the highest NEAT1 
transcript levels underexpressed all of them but BAG3. Since persistent activation of UPR in MM 
leads to apoptosis,10 the down-modulation of UPR pathway genes might suggest a survival attempt 
for myeloma cells. Furthermore, the functional enrichment analysis indicated that higher NEAT1 
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expression was associated with lower expression of DYNLL1, essential for p53 nuclear trafficking, 
with consequent transcriptional activation of genes involved in growth arrest and apoptosis in 
response to DNA damage.11 Consistently with reduced amount of p53 dynein-dependent nuclear 
translocation, enrichment analysis using GSEA tool evidenced that higher NEAT1 expression was 
correlated with weakened DNA repair-associated pathways. GSEA identified also enrichment in 
pathways associated with DNA synthesis and repair in MM with lower NEAT1 levels, and 
PI3K/AKT activation pathway in patients with high NEAT1 expression (Figure 2), in agreement 
with recent data describing NEAT1 as crucial player in suppressing transformation in response to 
oncogenic signals.12 For completeness, GSEA analysis was run in the #GSE2658 series, which 
confirmed significance in PI3KT/AKT activation pathway (Supplementary Table S6). 
Subsequently, we found that high NEAT1 expression was associated with 27 overexpressed 
and 2 underexpressed lncRNA transcripts (Figure 3 and Supplementary Table S7). Although most 
of these are virtually uncharacterized, three overexpressed ncRNAs, namely the two miRNA 
precursors MIR22HG and MIR29A, and C3orf35 (Figure 3), have been already reported in the 
context of MM. In particular, MIR22HG located at 17p13 was underexpressed in different solid 
tumors13 and in MM.4 It produces the mature miR-22, positively associated with progression free 
survival (PFS) in pPCL.14 In our cohort of patients, no differences in MIR22HG expression were 
appreciable among healthy donors, MM and PCL samples. MIR29A, mapped at 7q32, was 
overexpressed in MM showing the highest NEAT1 level. From MIR29A originate 2 miRNAs, miR-
29a and miR-29b-1, whose tumor suppressor activities have been well documented in MM.15 With 
regard to the expression levels of lncRNA, no significant differences were evidenced between 
MIR29A expression in healthy and pathological samples, the latter showing very heterogeneous 
expression pattern. Finally, C3orf35, mapped at 3p22, was recently described as overexpressed in 
MM versus normal control,4 although this data was not confirmed in our microarray dataset.  
 To evaluate the potential prognostic value of NEAT1 in MM, we analyzed a retrospectively 
collected proprietary dataset including 55 MM at diagnosis for whom clinical data were available, 
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over a median follow-up of 54 months. In particular, we assessed the expression of both global 
NEAT1 gene and the longer NEAT1_2 transcript separately by qRT-PCR, both of them correlated 
with neither overall survival nor the time to next treatment (Supplementary Table S8). Furthermore, 
we extended the qRT-PCR analysis to 12 additional MM patients (seven of them included in the 55-
sample dataset) for whom we had serial samples at the onset and relapse, but even in this case no 
significant variation in NEAT1 expression was observed (Supplementary Figure S6). Finally, we 
evaluated the NEAT1 prognostic significance in the TT2/TT3 trials cohort, showing no significant 
correlation between NEAT1_1 isoform expression and OS (Supplementary Figure S7). 
In conclusion, MM significantly overexpresses NEAT1, although, based on the available data, 
its deregulation appears do not directly affect the patient’s prognosis. However, the putative 
NEAT1 involvement in different mechanisms of cellular stress response, such as the UPR and p53 
pathways, makes it a confident candidate for further studies in a perspective of targeted therapy in 
the disease. 
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Figure Legends 
Figure 1: NEAT1 expression by GeneChip® Human Gene 2.0 ST arrays. A. Boxplot of 
NEAT1 expression shows a significant upregulation in pathological MM, pPCL and sPCL samples 
as compared with healthy control based on Dunn test (* means p-values <0.01). B. Boxplot of 
NEAT1 expression doesn’t show any significant correlation with group membership defined by 
t(11;14), t(4;14), MAF translocation, and hyperdiploid status. C. NEAT1 expression by RNA 
sequencing. Visualization of RNA-seq data: zoomed view of the NEAT1 lncRNA region; the 
coverage bigWig files generated using bamCoverage function in deeptools 
(http://deeptools.readthedocs.io/en/latest/content/tools/bamCoverage.html) and the human genome 
annotation file (GENCODE v.25) were loaded into the Integrated Genome Viewer (IGV 
[http://www.broadinstitute.org/igv/]. The y axis shows the scaled number of reads mapping to each 
location of the genome in the NEAT1 region (x axis) schematically reported below together with 
qRT-PCR primers. Each lane represents a MM patient: different colors refer to the sample 
molecular characteristic indicated at the left. In order to compare samples, coverage values from all 
patients were group-scaled. D. Boxplot of NEAT1_1 and NEAT1_2 expression by RNA-seq 
showing that the shorter transcript is expressed approximately 10-fold higher than the longer 
isoform. Transcript abundance was estimated as Fragments Per Kilobase per Million mapped reads 
(FPKM). E. Pearson analysis correlating NEAT1 total expression (x-axis) with the long transcript 
expression (y-axis). Correlation coefficient R and significant p-value are reported.  
 
Figure 2: Functional annotation of NEAT1 signature in MM. A. Enrichment plots of four 
selected gene sets detected by GSEA. The green curves show the enrichment score and reflect the 
degree to which each gene (black vertical lines) is represented at the bottom of the ranked gene list. 
Genes contributing to the core enrichment (C.E.) in the gene set are indicated in bold with Y. B. 
Heatmap of the 138 differentially expressed genes identified by comparing the first vs fourth 
quartile of 50 MM patients stratified into four groups based on NEAT1 expression level. 
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Figure 3: lncRNAs differentially expressed based on NEAT1 expression. A. Heatmap of the 30 
differentially expressed lncRNAs identified by comparing the first vs fourth quartile of 50 MM 
patients stratified into four groups based on NEAT1 expression level. B. Boxplot of MIR22HG, 
MIR29A, and C3orf35 expression levels in 4N, 50MM and 15 PCL samples profiled on 
GeneChip® Human Gene 2.0 ST arrays.  
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Supplementary Materials and Methods  
Samples 
We investigated a cohort of 50 MM patients representative of the major molecular characteristics 
of the disease, 9 primary PCLs (pPCL) and 6 secondary PCLs (sPCL) and four normal controls 
(purchased from Voden, Medical Instruments IT) (Table 1). PCs (>90%) were puriﬁed from bone 
marrow aspirates using CD138 immunomagnetic microbeads (MidiMACS system, Miltenyi Biotec, 
Auburn, CA). All the samples were characterized by fluorescence in situ hybridization (FISH) for the 
ploidy status and the presence of 17p13 or 13q14 deletions, 1q gain and the most frequent IGH 
chromosomal translocations t(11;14), t(4;14), t(14;16) and t(14;20), as previously described.1 The 
mutations pattern of BRAF, NRAS, KRAS, P53, FAM46C and DIS3 genes have been previously 
investigated by next-generation sequencing.2-4 Written informed consent was obtained from all 
patients in accordance with the declaration of Helsinki. The study was approved by the Ethical 
Committee of the University of Milan (N° 24/15, May 06 2015). 
 
Gene Expression Profiling 
All MM and PCL patients along with the 4 BM PC normal controls were profiled on GeneChip® 
Human Gene 2.0 ST arrays (Affymetrix Inc., Santa Clara, CA). Total RNA samples were processed 
according to manufacturer’s procedure. Normalized expression values were obtained using Robust 
Multi Array Average (RMA) procedure and annotations based on GENCODE v25, Ensembl v87 
(Chip Definition File available at 
http://brainarray.mbni.med.umich.edu/Brainarray/Database/CustomCDF/21.0.0/genecodet.asp). CDF file 
was customized in order to withdraw probes that map to regions where ambiguous detection due to 
transcript overlap might occur. In this way, the expression levels of 10138 unique lncRNAs were 
obtained. The list of differentially expressed genes or lncRNAs between high and low NEAT1 
expressing samples was gathered by Significant Analysis of Microarrays v5.00, using the tool 
provided for the shiny package in R software (https://github.com/MikeJSeo/SAM), as previously 
described.5 
The list of differentially expressed genes was submitted to the ToppGene Suite portal 
(http://toppgene.cchmc.org) for functional enrichment analysis using the ToppFun application. 
Microarray data were globally analyzed by Gene Set Enrichment Analysis (GSEA, software v.2.2.1).6 
Gene sets were considered significant with nominal p-value < 0.05. All the data have been deposited 
in the NCBI Gene Expression Omnibus database (GEO; http//www.ncbi.nlm.nih.gov/geo) and are 
accessible under accession #GSE116294.  
 
RNA sequencing (RNA-seq) 
The sequencing data have been previously generated and were publicly available at GEO 
repository under accession #GSE109342. Transcript abundance was estimated as previously 
described 7 and was reported as FPKM, Fragments Per Kilobase per Million mapped reads. Cufflinks 
estimates a likelihood of relative abundances for all the possible sets of transcripts based on the 
identified ‘incompatible’ fragments that stemmed from differently spliced mRNA isoforms, 
producing a numerical value that best explains the observed fragments. 
 
Quantitative real-time PCR (qRT-PCR) 
For qRT-PCR, 100 ng of total RNA underwent reverse transcription using random primer mix 
and reagents from INVITROGEN (Life Technologies, Foster City, CA). Real-time PCR to validate 
NEAT1 was performed using 10 ng of total RNA and SYBR™ Green master mix with custom 
primers (Supplementary Table S3) as previously described. 5  
 
Statistical analysis  
 Conventional statistical tests were applied as reported in the manuscript using standard 
functions in base R package (Kendall Tau correlation, Pearson correlation, Dunn test, and Wilcoxon 
rank-sum tests). 
 We used the Cox proportional hazards model in the globaltest function of R software (with 
100,000 permutation) to test the association between NEAT1 expression levels, assumed as 
continuous variables and overall survival (OS) or time to next treatment (TNT) as clinical outcome.  
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Supplementary Figure S1. Boxplot of NEAT1 expression does not show any significant correlation 
with group membership defined by deletions of chromosome 13q, 17p13, and gain of chromosome 
1q, the presence of mutations of the MAPK-pathway (BRAF, NRAS, or KRAS), DIS3 or FAM46C.  
 
 
 
Supplementary Figure S2. A. Validation of GEP results by qRT-PCR with the 5’-primers. PCR data 
are represented by grouped-columns with the 2-Ct scale on the right side; GEP data are reported as 
histogram with the corresponding log-scale at the left side, the dotted tendency line is also indicated. 
B. Validation of RNA-seq data by qRT-PCR with the 5’-primers. PCR data are represented by 
grouped-columns with the 2-Ct scale on the right side; RNA-seq data are reported as histogram with 
the corresponding scale at the left side. For both graphs, Kendall coefficient and significance are 
reported. 
 
 
 
 
  
Supplementary Figure S3. Boxplot of NEAT1 qRT-PCR expression in MM/PCL versus 5 
smoldering MM samples in proprietary dataset. 
 
  
Supplementary Figure S4. Boxplot of NEAT1 isoform expression in healthy donors, MGUS, 
smoldering MM and MM samples from GSE5900 and GSE2658 microarray series (legend indicates 
Kruskal test P-value; *=Dunn’s test P<0.05/2). 
  
Supplementary Figure S5. Pearson  analysis  correlating  NEAT1 total expression (x-axis) with the 
NONO or SFPQ (y-axis). R correlation coefficient and significance are reported. 
 
  
Supplementary Figure S6: Boxplot of NEAT1 qRT-PCR expression in 12 paired samples at onset 
and at relapse.  
 
 
 
 
 
  
Supplementary Figure S7: Kaplan – Meier estimated curves of the two groups deﬁned by NEAT1_1 
isoform high (blue) and low (red) expression levels in GSE2658 dataset. For representation, data 
stratified on the median expression level are shown. 
 
 
 
 
  
Supplementary Table S1. Molecular characteristics of 50 MM and 15 PCL patients. 
 
 MM PCL 
Sample 
Features 
Positive 
(%) 
Negative 
(%) 
Not 
available 
Positive 
(%) 
Negative 
(%) 
Not 
available 
HD  15 (30) 32 (64) 3 0 15 (100) 0 
t(11;14)  12 (24) 38 (76) 0 3(20) 12(80) 0 
t(4;14) 12 (24) 38 (76) 0 3(20) 12(80) 0 
MAF-trx 5 (10) 45 (90) 0 6(40) 9(60) 0 
none 3 (6) 47 (94)  3(20) 12(80)  
del(17) 3 (6) 46 (92) 1 6(40) 9(60) 0 
del(13)  27 (54) 23 (46) 0 9(60) 6(40) 0 
1q-gain  24 (48) 20 (40) 6 7(47) 6(40) 2 
N-RAS 8 (16) 33 (66) 9 1(7) 11(73) 3 
K-RAS 12 (24) 29 (58) 9 1(7) 12(80) 2 
BRAF 
 
5 (10) 36 (72) 9 3(20) 10(67) 2 
DIS3 9 (18) 32 (64) 9 3(20) 9(60) 3 
P53 2(4) 38(76) 10 4(27) 9(60) 2 
FAM46C 3(6) 36(72) 11 0 13(87) 2 
 
 
 
 
 
 
Supplementary Table S2. Highly expressed lncRNAs displaying an average log2 expression >10. 
 
 
 
Log2 expression >10 chromosome 
LINC01001 11p15 
NEAT1 11q13 
MALAT1 11q13 
RP11-658F2.8 11q13 
RP11-736K20.5 11q14 
LINC01089 12q24 
LRRC75A-AS1-014 17p11 
LINC01480 19q13 
RP11-161I10.1 1q31 
TUG1 22q12 
AC074289.1 2p14 
FGD5-AS1 3p25 
RP11-325F22.2 7q22 
LINC-PINT 7q32 
EBLN3 9p13 
FTX Xq13 
CDR1-AS Xq27 
Supplementary Table S3. Sequences of the primers used for qRT-PCR. 
 
 
 
 
  
PRIMER Sequence 5' - 3' 
NEAT1 5’-region Forward GCCTTGTAGATGGAGCTTGC 
NEAT1 5’-region Reverse GCACAACACAATGACACCCT 
NEAT1 3’-region Forward GGCCAGAGCTTTGTTGCTTC 
NEAT1 3’-region Reverse GGTGCGGGCACTTACTTACT 
Supplementary Table S4. Modulated genes resulting from SAM (Significant Analysis of Microarray 
algorithm) analyses (https://github.com/MikeJSeo/SAM) comparing MM patients expressing high 
NEAT1 levels (IV quartile) and low NEAT1 levels (I quartile), ordered based on (d)-score. 8  
 
Gene Name Score(d) 
Fold 
Change 
 TEX14 4.84 5.64 
 LCA5 4.72 2.54 
 LRRC39 4.71 3.57 
 TRAF6 4.61 1.94 
 FAM160B1 4.58 2.26 
 BAG3 4.55 2.35 
 RIPK1 4.54 1.94 
 CRABP2 4.45 1.89 
 PIK3C2B 4.43 1.82 
 ARID5B 4.34 3.13 
 TBC1D15 4.28 2.00 
 FBXL3 4.19 2.17 
 SLC39A1 4.19 1.46 
 ATP13A3 4.16 1.91 
 UBE2B 4.14 1.84 
 MAD2L2 4.09 1.64 
 DYRK1A 4.09 2.33 
 GORAB 4.02 1.96 
 ZNF460 4.00 1.72 
 C16orf72 3.98 1.61 
 WDR26 3.97 2.30 
 DCAF8 3.96 1.89 
 CASP7 3.94 1.95 
 SMYD4 -5.57 0.49 
 WDR70 -5.04 0.58 
 NEMP1 -4.92 0.54 
 CCR2 -4.90 0.18 
 CCDC77 -4.90 0.53 
 DUSP19 -4.71 0.33 
 GTF2H2C -4.66 0.55 
 RCCD1 -4.60 0.67 
 SNUPN -4.59 0.47 
 CBX1 -4.56 0.48 
 POLH -4.51 0.36 
 ALDH5A1 -4.38 0.43 
 SPATA5 -4.29 0.62 
 ELMO1 -4.28 0.58 
 EVI2A -4.28 0.37 
 USP28 -4.27 0.46 
 SENP8 -4.25 0.68 
 CEP78 -4.24 0.54 
 INIP -4.23 0.55 
 NAPEPLD -4.22 0.45 
 POC5 -4.21 0.50 
 RNASEH2A -4.18 0.55 
 ASXL2 -4.17 0.48 
 METTL7A -4.17 0.47 
 NCAPD2 -4.16 0.50 
 ELOF1 -4.15 0.55 
 DAXX -4.15 0.57 
 ERMP1 -4.14 0.54 
 DNMT1 -4.14 0.41 
 RASA1 -4.13 0.60 
 CKAP5 -4.12 0.54 
 CLINT1 -4.10 0.64 
 APEH -4.09 0.59 
 BTK -4.09 0.38 
 ZNF260 -4.06 0.30 
 HACD3 -4.05 0.47 
 NFYA -4.02 0.60 
 GEMIN4 -4.01 0.64 
 ASF1B -3.99 0.44 
 EHBP1 -3.98 0.50 
 PPP5C -3.98 0.47 
 SKA2 -3.98 0.44 
 DROSHA -3.97 0.61 
 MRPL34 -3.97 0.46 
 IRF2 -3.94 0.49 
 DFFB -3.94 0.61 
 SCAI -3.94 0.52 
 MUM1 -3.93 0.59 
 TAS2R5 -3.92 0.65 
 SLC38A9 -3.90 0.55 
 DPF2 -3.89 0.55 
 CCR3 -3.89 0.63 
 RSBN1L -3.87 0.57 
 TBC1D5 -3.87 0.57 
 DBP -3.85 0.56 
 ST3GAL5 -3.83 0.43 
 SLC25A40 -3.82 0.53 
 UCP2 -3.81 0.50 
 RAD51C -3.80 0.49 
 THYN1 -3.79 0.51 
 HN1L -3.79 0.57 
 BAG2 -3.79 0.51 
 TTLL11 -3.75 0.44 
 LARS -3.75 0.48 
 GRHPR -3.74 0.57 
 TAS2R4 -3.73 0.66 
 DYNLL1 -3.72 0.41 
 MOCS2 -3.71 0.48 
 TYSND1 -3.71 0.69 
 BCS1L -3.70 0.48 
 TUBB -3.70 0.67 
 ABCG2 -3.69 0.21 
 ZNF718 -3.69 0.57 
 TMEM245 -3.68 0.64 
 ADRB2 -3.67 0.50 
 SKP2 -3.67 0.46 
 GCDH -3.66 0.64 
 GATC -3.66 0.56 
 KANK1 -3.65 0.37 
 RHOT1 -3.65 0.53 
 DDX10 -3.65 0.53 
 RACGAP1 -3.65 0.45 
 FARSA -3.64 0.55 
 RNF145 -3.64 0.55 
 OSGEPL1 -3.64 0.48 
 CWC27 -3.63 0.65 
 ARHGEF3 -3.62 0.52 
 ODF2 -3.59 0.63 
 EXOSC2 -3.58 0.54 
 DPY30 -3.58 0.53 
 C9orf114 -3.57 0.52 
 TLR10 -3.56 0.40 
 CHST12 -3.56 0.54 
 TBCK -3.55 0.63 
 TOR1B -3.54 0.60 
 TUBGCP4 -3.53 0.52 
 RBM4B -3.52 0.63 
 POLR3K -3.52 0.46 
 KYAT1 -3.52 0.72 
 NEURL4 -3.52 0.55 
 PCDHGB6 -3.52 0.45 
 DOCK8 -3.52 0.58 
 HMMR -3.50 0.48 
 DCAF7 -3.48 0.62 
 CNNM2 -3.47 0.60 
 MRM2 -3.47 0.71 
 DNAJA3 -3.46 0.54 
 PREB -3.46 0.46 
 TMEM138 -3.45 0.56 
 ATP6V0E1 -3.45 0.65 
 C1orf186 -3.44 0.19 
 HIKESHI -3.43 0.57 
 MRPL17 -3.43 0.58 
 HSH2D -3.43 0.49 
 ADAM22 -3.43 0.37 
 
 
  
Supplementary Table S5. List of the significantly enriched Gene sets for the 138 differentially expressed genes, by ToppGene suite analysis. Q-
value calculated according to Benjamini&Hochberg correction. 
 
Category Source ID Name q-value  
Hit Count in 
Query List 
Hit Count 
in Genome 
Hit in Query List 
Drug CTD ctd:D003375 Coumestrol 3.26E-04 32 1796 
RAD51C,MRM2,NEMP1,ATP6V0E1,RASA1,RNASEH2
A,RCCD1,DOCK8,BAG3,BAG2,CKAP5,CASP7,SKA2,H
MMR,TUBGCP4,SKP2,BCS1L,EXOSC2,TUBB2A,ZNF2
60,UBE2B,PPP5C,CEP78,ZNF718,ASF1B,NCAPD2,GE
MIN4,RACGAP1,MAD2L2,METTL7A,RHOT1,DNMT1 
Interaction   int:DYNLL1 DYNLL1 interactions 6.88E-04 12 224 
LCA5,POLH,DYRK1A,HMMR,CCDC77,RHEX,KANK1,
ASF1B,DYNLL1,CLINT1,DNMT1,DCAF7 
Coexpression GeneSigDB 
18757322-
TableS1 
Human Breast_Creighton08_2154genes 1.74E-03 29 1739 
RAD51C,MRM2,NEMP1,POLR3K,TBC1D15,RNASEH2
A,TBC1D5,BAG3,WDR70,APEH,HMMR,DBP,CRABP2,
BCS1L,EXOSC2,TUBB2A,FARSA,KANK1,PPP5C,ASF
1B,OSGEPL1,UCP2,ARID5B,NCAPD2,RACGAP1,CHS
T12,ALDH5A1,METTL7A,DNMT1 
Coexpression 
MSigDB C2: CGP 
Curated Gene Sets 
(v6.0) 
M80 
Genes up-regulated in TC71 and EWS502 cells (Ewing's 
sarcoma) by EWSR1-FLI1  [GeneID=2130;2314] as inferred 
from RNAi knockdown of this fusion protein. 
1.74E-03 24 1276 
RAD51C,MRM2,NEMP1,RNASEH2A,HACD3,BAG2,L
ARS,CKAP5,SKA2,HMMR,TUBGCP4,SKP2,EXOSC2,S
MYD4,PPP5C,CEP78,ASF1B,TMEM245,NCAPD2,NFY
A,GEMIN4,RACGAP1,POC5,DNMT1 
Coexpression 
MSigDB C2: CGP 
Curated Gene Sets 
(v6.0) 
M10351 
Genes down-regulated in T24 (bladder cancer) cells in 
response to the photodynamic therapy (PDT) stress. 
2.94E-03 16 637 
RAD51C,POLR3K,DCAF8,GATC,ERMP1,SKP2,BCS1L,
DFFB,FARSA,KANK1,ADRB2,THYN1,UCP2,GEMIN4,
MRPL34,ALDH5A1 
Coexpression 
MSigDB C2: CGP 
Curated Gene Sets 
(v6.0) 
M14427 
Genes down-regulated in nasopharyngeal carcinoma (NPC) 
compared to the normal tissue. 
2.94E-03 24 1367 
RAD51C,MRM2,NEMP1,NAPEPLD,RNASEH2A,HACD
3,RCCD1,LARS,CKAP5,HMMR,TUBGCP4,CCDC77,SK
P2,ADAM22,ZNF260,DNAJA3,CEP78,SLC25A40,OSGE
PL1,GORAB,CBX1,RACGAP1,RHOT1,SCAI 
Transcription 
Factor Binding 
Site 
  
RCGCANGCGY 
V$NRF1 Q6 
RCGCANGCGY_V$NRF1_Q6 3.11E-03 17 654 
TBC1D15,RASA1,TBC1D5,POLH,DPF2,HMMR,TUBG
CP4,EXOSC2,PREB,MRPL17,DNAJA3,DFFB,DPY30,N
FYA,GEMIN4,MOCS2,DNMT1 
Coexpression 
MSigDB C7: 
Immunologic 
Signatures (v6.0) 
M5300 
Genes down-regulated in comparison of untreated CD4 
[GeneID=920] memory T cells from old donors versus those 
treated with TSST at 40 h. 
3.51E-03 9 200 
RAD51C,POLR3K,RNASEH2A,RBM4B,CKAP5,IRF4,S
NUPN,HMMR,RACGAP1 
Coexpression 
MSigDB C7: 
Immunologic 
Signatures (v6.0) 
M8271 
Genes down-regulated in B lymphocytes stimulated by anti-
IgM: 3h versus 16h. 
3.51E-03 9 200 
EHBP1,LRRC39,NAPEPLD,RNASEH2A,DOCK8,WDR7
0,DROSHA,SPATA5,RHOT1 
Coexpression GeneSigDB 
17952126-
SuppTable2 
Human Bladder_Buytaert08_651genes 3.51E-03 15 608 
RAD51C,POLR3K,DCAF8,ERMP1,SKP2,BCS1L,DFFB,
FARSA,KANK1,ADRB2,THYN1,UCP2,GEMIN4,MRPL
34,ALDH5A1 
Coexpression GeneSigDB 
18362358-
Table11 
Human Leukemia_Calln08_60genes 3.70E-03 5 41 RAD51C,LARS,OSGEPL1,ASXL2,RHOT1 
Coexpression 
MSigDB H: 
Hallmark Gene 
Sets (v6.0) 
M5922 
Genes up-regulated during unfolded protein response, a 
cellular stress response related to the endoplasmic reticulum. 
3.81E-03 7 113 
BAG3,EXOSC2,TUBB2A,DDX10,PREB,NFYA,GEMIN
4 
Coexpression 
MSigDB C2: CGP 
Curated Gene Sets 
(v6.0) 
M1105 
Genes down-regulated in ME-A cells (breast cancer) 
undergoing apoptosis in response to doxorubicin 
[PubChem=31703]. 
3.81E-03 27 1781 
RAD51C,TRAF6,DCAF8,RIPK1,RCCD1,HIKESHI,CKA
P5,DYRK1A,DUSP19,TUBGCP4,SKP2,BCS1L,EXOSC2
,ELMO1,DDX10,MRPL17,ST3GAL5,DPY30,NCAPD2,N
FYA,CBX1,RACGAP1,ATP13A3,MRPL34,MAD2L2,RN
F145,NEURL4 
Coexpression 
MSigDB C2: CGP 
Curated Gene Sets 
(v6.0) 
M1463 
Genes up-regulated in Caco-2 cells (intestinal epithelium) 
after coculture with the probiotic bacteria L. casei for 24h. 
3.81E-03 14 556 
NEMP1,POLR3K,ATP6V0E1,HMMR,SKP2,EXOSC2,TU
BB2A,THYN1,DROSHA,GEMIN4,RACGAP1,DYNLL1,
ATP13A3,DNMT1 
Coexpression 
Atlas 
FaceBase_RNAseq 
Facebase_RNAs
eq_e8.5_Floor 
Plate_2500_K3 
FacebaseRNAseq_e8.5_Floor Plate_top-relative-expression-
ranked_2500_k-means-cluster#3 
3.94E-03 17 708 
ATP6V0E1,BAG3,BAG2,LARS,TMEM138,APEH,DUSP
19,TYSND1,SKP2,WDR26,DNAJA3,FARSA,PPP5C,CEP
78,ASF1B,NFYA,GEMIN4 
Coexpression 
Atlas 
PCBC 
ratio_ECTO_vs_
SC_2500_K2 
ratio_induced-Ectoderm_vs_StemCell_top-relative-
expression-ranked_2500_k-means-cluster#2 
3.94E-03 13 419 
MRM2,POLR3K,DCAF8,SPOUT1,HACD3,HIKESHI,LA
RS,TMEM138,TUBGCP4,THYN1,DROSHA,GEMIN4,R
ACGAP1 
Coexpression 
MSigDB C2: CGP 
Curated Gene Sets 
(v6.0) 
M2368 
Genes up-regulated during later stage of differentiation of 
Oli-Neu cells (oligodendroglial precursor) in response to 
PD174265 [PubChem=4709]. 
4.43E-03 14 570 
NEMP1,CKAP5,CASP7,SKA2,HMMR,CCDC77,SKP2,T
HYN1,ASF1B,NCAPD2,RACGAP1,DYNLL1,DNMT1,D
CAF7 
Coexpression 
MSigDB C2: CGP 
Curated Gene Sets 
(v6.0) 
M9516 
Genes constituting the BRCA2-PCC network of transcripts 
whose expression positively correlated (Pearson correlation 
coefficient, PCC >= 0.4) with that of BRCA2 [GeneID=675] 
across a compendium of normal tissues. 
4.43E-03 12 423 
RAD51C,NEMP1,RNASEH2A,CKAP5,HMMR,SKP2,EX
OSC2,NCAPD2,NFYA,CBX1,CLINT1,DNMT1 
Coexpression GeneSigDB 
17229949-
TableS4 
Human Breast_Liu07_186genes 4.43E-03 8 172 
SLC38A9,LARS,DPF2,FAM160B1,GORAB,ATP13A3,M
ETTL7A,DCAF7 
Coexpression GeneSigDB 
16597596-
TableS2-3 
Human Leukemia_Wilson06_50genes_DifferentialClusterC 4.84E-03 5 49 GCDH,BCS1L,EXOSC2,DYNLL1,DCAF7 
Coexpression 
MSigDB C2: CGP 
Curated Gene Sets 
(v6.0) 
M2228 
Genes down-regulated in erythroid progenitor cells from fetal 
livers of E13.5 embryos with KLF1 [GeneID=10661] 
knockout compared to those from the wild type embryos. 
5.38E-03 28 1972 
POLR3K,RIPK1,DOCK8,HIKESHI,POLH,CASP7,EVI2A
,SKA2,TUBGCP4,FAM160B1,SKP2,ELOF1,ELMO1,INI
P,CCR2,UBE2B,THYN1,PPP5C,DPY30,BTK,NFYA,RA
CGAP1,TOR1B,RNF145,SPATA5,CRAMP1,RHOT1,DN
MT1 
Coexpression GeneSigDB 18387200-Genes Human Breast_Mutarelli08_1488genes 6.36E-03 20 1169 
RAD51C,POLR3K,RNASEH2A,POLH,LARS,CKAP5,H
MMR,TUBGCP4,CRABP2,SKP2,BCS1L,EXOSC2,DDX
10,MRPL17,FARSA,ASF1B,NCAPD2,GEMIN4,RACGA
P1,MAD2L2 
Coexpression 
MSigDB C2: CGP 
Curated Gene Sets 
(v6.0) 
M18120 
Genes down-regulated in HCT116 cells (colon cancer) by 
expression of MIR192 or MIR215 [GeneID=406967;406997] 
at 24 h. 
6.36E-03 17 893 
NEMP1,SLC39A1,HACD3,LARS,DYRK1A,CASP7,ER
MP1,HMMR,INIP,CEP78,SLC25A40,NFYA,RACGAP1,
CHST12,TOR1B,ALDH5A1,RSBN1L 
Coexpression 
MSigDB C2: CGP 
Curated Gene Sets 
(v6.0) 
M2156 
Genes up-regulated in MCF7 cells (breast cancer) at 24 h of 
estradiol [PubChem=5757] treatment. 
6.36E-03 10 324 
NEMP1,RNASEH2A,SKP2,EXOSC2,DDX10,CEP78,AS
F1B,NCAPD2,RACGAP1,DNMT1 
Coexpression 
MSigDB C7: 
Immunologic 
Signatures (v6.0) 
M3594 
Genes down-regulated in comparison of CD8 T cells at 0 h 
versus those at 24 h after stimulation with antigen-B7-1. 
6.36E-03 8 200 
POLR3K,CKAP5,IRF4,ELOF1,MRPL17,CBX1,RHOT1,
DNMT1 
Coexpression 
MSigDB C7: 
Immunologic 
Signatures (v6.0) 
M4248 
Genes down-regulated in comparison of CD4 [GeneID=920] 
T cells treated with IL4 [GeneID=3565] and anti-IL12 at 1.5 
h versus those at 72 h. 
6.36E-03 8 200 
RAD51C,POLR3K,RCCD1,IRF2,THYN1,GRHPR,ASF1
B,MAD2L2 
Coexpression 
MSigDB C7: 
Immunologic 
Signatures (v6.0) 
M3830 
Genes up-regulated in comparison of dendritic cells (DC) 
stimulated with poly(I:C) (TLR3 agonist) at 2 h versus DC 
cells stimulated with Pam3Csk4 (TLR1/2 agonist) at 2 h. 
6.36E-03 8 200 
RASA1,GATC,EVI2A,SKP2,DNAJA3,CHST12,SPATA5,
DNMT1 
Coexpression 
MSigDB C7: 
Immunologic 
Signatures (v6.0) 
M8103 
Genes up-regulated in unstimulated IL10 [GeneID=3586] 
knockout macrophages versus NFKB1 and IL10 
[GeneID=4790;3586] knockout macrophages stimulated by 
LPS. 
6.36E-03 8 200 
RASA1,APEH,EVI2A,SKA2,DPF2,CCDC77,RACGAP1,
HSH2D 
Coexpression 
MSigDB C7: 
Immunologic 
Signatures (v6.0) 
M5303 
Genes down-regulated in comparison of untreated CD4 
[GeneID=920] memory T cells from old donors versus those 
treated with TSST at 72 h. 
6.36E-03 8 200 
RAD51C,RNASEH2A,RBM4B,CKAP5,IRF4,SNUPN,H
MMR,RACGAP1 
Coexpression 
MSigDB C7: 
Immunologic 
Signatures (v6.0) 
M3326 
Genes up-regulated in comparison of polysome bound 
(translated) mRNA versus total mRNA in dendritic cells. 
6.36E-03 8 200 
SPOUT1,BAG3,BCS1L,DNAJA3,GORAB,RACGAP1,A
RHGEF3,CRAMP1 
Coexpression 
MSigDB C7: 
Immunologic 
Signatures (v6.0) 
M3591 
Genes down-regulated in comparison of CD8 T cells at 0 h 
versus those at 24 h after stimulation with IL12 . 
6.36E-03 8 200 
POLR3K,CKAP5,IRF4,CRABP2,ELOF1,MRPL17,NEUR
L4,RHOT1 
Coexpression 
MSigDB C7: 
Immunologic 
Signatures (v6.0) 
M4298 
Genes down-regulated in comparison of naive CD8 T cells 
versus effector CD8 IL2RA [GeneID=3559] low T cells at. 
6.36E-03 8 200 
RAD51C,NAPEPLD,HIKESHI,DUSP19,ERMP1,INIP,DR
OSHA,CHST12 
Coexpression 
MSigDB C7: 
Immunologic 
Signatures (v6.0) 
M9922 
Genes up-regulated in B lymphocytes: untreated versus anti-
IgM for 6h. 
6.36E-03 8 200 
EHBP1,TBC1D5,CKAP5,ELMO1,SLC25A40,UCP2,RHO
T1,DNMT1 
Coexpression 
MSigDB C7: 
Immunologic 
Signatures (v6.0) 
M6925 
Genes up-regulated in B lymphocytes: control versus anti 
IgM and CpG oligodeoxynucleotide 1826. 
6.36E-03 8 200 
RNASEH2A,HIKESHI,DUSP19,HMMR,ZNF260,GRHPR
,CHST12,METTL7A 
Coexpression GeneSigDB 
17150101-
TableS1l 
Human Breast_Troester06_436genes-up-DOX-ZR75-1 6.52E-03 10 329 
RNASEH2A,RCCD1,CASP7,HMMR,SKP2,SLC25A40,A
SF1B,NCAPD2,RACGAP1,DNMT1 
Coexpression 
MSigDB C2: CGP 
Curated Gene Sets 
(v6.0) 
M1744 
Genes with promoters bound by E2F4 [GeneID=1874] in 
unstimulated hybridoma cells. 
6.53E-03 15 727 
NEMP1,HIKESHI,SKA2,HMMR,SKP2,EXOSC2,INIP,A
SF1B,DROSHA,NCAPD2,NFYA,CBX1,RACGAP1,DN
MT1,DCAF7 
Coexpression 
MSigDB C2: CGP 
Curated Gene Sets 
(v6.0) 
M1195 
Genes up-regulated in hepatocellular carcinoma (HCC) 
compared to normal liver samples. 
8.23E-03 15 744 
NEMP1,SLC39A1,HACD3,TBC1D5,BAG2,ERMP1,HM
MR,TYSND1,SKP2,ELMO1,ASF1B,NCAPD2,NFYA,CB
X1,DCAF7 
Coexpression 
MSigDB C2: CGP 
Curated Gene Sets 
(v6.0) 
M5611 
Genes constituting the BRCA1-PCC network of transcripts 
whose expression positively correlated (Pearson correlation 
coefficient, PCC >= 0.4) with that of BRCA1 [GeneID=672] 
across a compendium of normal tissues. 
8.23E-03 24 1651 
RAD51C,NEMP1,RNASEH2A,CKAP5,CASP7,IRF2,IRF
4,DAXX,HMMR,SKP2,ADAM22,KYAT1,DDX10,FARS
A,BTK,UCP2,NCAPD2,GEMIN4,ATP13A3,CLINT1,AB
CG2,ALDH5A1,DNMT1,DCAF7 
Coexpression GeneSigDB 
19139136-
TableS3 
Human Prostate_John-Aryankalayil09_2212genes 8.23E-03 23 1547 
NEMP1,RCCD1,ZNF460,POLH,SKA2,DUSP19,HMMR,
CCDC77,CRABP2,SKP2,KYAT1,SLC25A40,ST3GAL5,
PIK3C2B,ASF1B,OSGEPL1,TTLL11,GORAB,ARID5B,
NCAPD2,RACGAP1,CLINT1,RNF145 
Coexpression 
MSigDB C2: CGP 
Curated Gene Sets 
(v6.0) 
M4077 
Genes identified by method 2 as coordinately down-regulated 
late in HMEC cells (mammary epithelium) during acinar 
development in vitro. 
8.23E-03 9 277 
RNASEH2A,HACD3,CKAP5,SKP2,BCS1L,PREB,MRPL
17,DROSHA,RACGAP1 
Coexpression 
MSigDB C2: CGP 
Curated Gene Sets 
(v6.0) 
M1915 
Genes down-regulated in neural stem cells (NSC) at 60 h 
after cre-lox knockout of TLX (NR2E1) [GeneID=7101]. 
8.23E-03 9 277 
RAD51C,POLR3K,HMMR,SKP2,EXOSC2,ASF1B,NCA
PD2,RACGAP1,DNMT1 
 
 
Supplementary Table S6. Reactome gene sets obtained using Gene Sets Enrichment Analysis showing significant modulation between patients with 
low and high NEAT1 expression level. NES: Normalized Enrichment Score. Pathways in bold were found significantly enriched also in GSEA 
analysis run in GSE2658 series. 
 
Gene set name 
Gene set 
size 
NES 
p-
value 
Gene List 
PI3K AKT ACTIVATION 36 1.53 0.028 
AKT3, PIK3CA, PHLPP1, IRS1, IRS2, CDKN1A, CHUK, NR4A1, CDKN1B, RICTOR, FOXO1, TRIB3, NTRK1, MDM2, 
AKT1, RHOA, CASP9, PIK3R1, FOXO4, NGF, MLST8, CREB1, BAD, PDPK1, MTOR, FOXO3, RPS6KB2, AKT2, 
PIK3CB, GSK3A, TSC2, MAPKAP1, AKT1S1, THEM4, PIK3R2, PTEN  
AMINO ACID TRANSPORT ACROSS 
THE PLASMA MEMBRANE 
31 1.51 0.043 
SLC7A5, SLC3A1, SLC7A1, SLC6A15, SLC7A11, SLC43A2, SLC3A2, SLC6A6, SLC7A8, SLC7A10, SLC6A12, 
SLC38A5, SLC7A9, SLC36A2, SLC7A3, SLC6A14, SLC7A2, SLC16A10, SLC38A2, SLC7A6, SLC7A7, SLC6A19, 
SLC38A1, SLC38A3, SLC43A1, SLC6A18, SLC1A5, SLC36A1, SLC38A4, SLC1A4, SLC6A20 
SIGNAL TRANSDUCTION BY L1 34 1.47 0.033 
ITGA2B, ITGB3, ITGAV, RPS6KA2, RPS6KA6, RPS6KA4, EGFR, ITGB1, MAP2K1, RPS6KA5, RPS6KA3, FGFR1, 
CSNK2B, CSNK2A2, RAC1, NCAM1, CLTC, ITGA5, MAP2K2, CSNK2A1, NRP1, ITGA9, AP2A1, RPS6KA1, PAK1, 
AP2B1, MAPK1, MAPK3, CLTA, AP2A2, SH3GL2, AP2S1, AP2M1, L1CAM 
DIABETES PATHWAYS 122 1.40 0.042 
ATF3, DDIT3, DNAJB9, DIS3, GH1, GHRL, ARFGAP1, LMNA, CCL2, RAB27A, SHC1, EXOC8, ATF6, CTDSP2, 
DNAJC3, TSPYL2, KLF4, EXOC1, EIF2AK3, DNAJB11, MMP1, SLC30A7, ERN1, FKBP14, SERP1, KDELR3, 
ACADVL, LEP, STX1A, PAPPA2, EDEM1, VAMP2, IGF2, PDIA5, HDGF, SEC11C, TPP1, PLA2G7, EXOSC7, KIF5B, 
HERPUD1, ATF4, PCSK2, MBTPS1, IGFBP5, ZBTB17, MBTPS2, IGFBP1, EXOSC1, HSPA5, MBOAT4, GCG, SPCS1, 
SPCS2, SSR1, HSP90B1, SPCS3, EXOC3, SRPRB, PLG, IGF2BP3, PAPPA, EXOC2, IGFBP3, F2, NFYB, EXOSC9, 
KLK3, PDIA6, IGFBP6, MMP2, WIPI1, IGFBP4, EIF2S1, ADD1, IGFALS, EXOC4, EXOC5, SYVN1, ATP6V0D1, 
IGFBP2, EXOSC8, PCSK1, KHSRP, GOSR2, CALR, EXOSC6, DDX11, CXXC1, SEC11A, HYOU1, IGF2BP1, INS, 
SEC31A, GSK3A, CUL7, BCHE, PARN, CPE, YIF1A, XBP1, DCTN1, PPP2R5B, TATDN2, TLN1, ASNS, IGF2BP2, 
KLHDC3, MYO5A, EXOC6, EXTL3, WFS1, CTSG, SLC30A5, EXOSC4, NFYA, DCP2, EXOSC3, EXOSC2, EXOSC5, 
PREB, SNAP25 
PROCESSIVE SYNTHESIS ON THE 
LAGGING STRAND 
15 -1.69 0.000 FEN1, DNA2, LIG1, RPA2, POLD1, POLA1, POLD2, POLD4, POLD3, PRIM2, RPA3, POLA2, RPA1, PRIM1, PCNA 
FORMATION OF INCISION COMPLEX 
IN GG NER 
20 -1.69 0.024 
GTF2H4, RAD23B, CDK7, ERCC5, XPA, ERCC4, XPC, DDB1, CCNH, ERCC3, GTF2H3, ERCC1, RPA2, ERCC2, RPA3, 
GTF2H1, MNAT1, DDB2, RPA1, GTF2H2 
DESTABILIZATION OF MRNA BY 
KSRP 
16 -1.63 0.020 
DIS3, EXOSC7, EXOSC1, EXOSC9, AKT1, MAPK14, EXOSC8, KHSRP, EXOSC6, PARN, MAPK11, EXOSC4, DCP2, 
EXOSC3, EXOSC2, EXOSC5 
GLOBAL GENOMIC NER GG NER 32 -1.61 0.018 
GTF2H4, RFC5, RAD23B, CDK7, ERCC5, XPA, ERCC4, XPC, DDB1, CCNH, ERCC3, GTF2H3, RFC3, RFC2, ERCC1, 
LIG1, RPA2, ERCC2, POLD1, POLD2, POLE, POLD4, POLD3, RPA3, GTF2H1, MNAT1, RFC4, DDB2, POLE2, RPA1, 
PCNA, GTF2H2 
HOMOLOGOUS RECOMBINATION 
REPAIR OF REPLICATION 
INDEPENDENT DOUBLE STRAND 
BREAKS 
16 -1.60 0.020 
BRCA2, TP53BP1, MDC1, RAD50, RAD51, LIG1, NBN, RPA2, ATM, H2AFX, RAD52, MRE11A, RPA3, RPA1, BRCA1, 
BRIP1 
RESOLUTION OF AP SITES VIA THE 
MULTIPLE NUCLEOTIDE PATCH 
REPLACEMENT PATHWAY 
17 -1.57 0.042 
MPG, TDG, MBD4, FEN1, NTHL1, CCNO, POLB, MUTYH, APEX1, LIG1, POLD1, POLD2, OGG1, POLD4, POLD3, 
SMUG1, PCNA 
METABOLISM OF NUCLEOTIDES 69 -1.57 0.010 
AK5, PNP, ADSS, NT5E, UPB1, GUK1, NT5C2, UPP1, NT5C1B, NT5C1A, TXN, GLRX, AMPD1, UCK2, ADSSL1, TK2, 
AMPD2, CMPK1, ADK, HPRT1, GSR, IMPDH1, DPYD, UPP2, DCTD, UMPS, AMPD3, GDA, APRT, PFAS, TXNRD1, 
AK1, DUT, NT5C, AGXT2, ADAL, GMPR, DGUOK, ADSL, GMPS, UCK1, GMPR2, TYMP, CAT, NT5M, RRM1, DPYS, 
NME1, IMPDH2, ADA, AK2, ATIC, XDH, NME4, CTPS2, DHODH, PPAT, GART, CDA, RRM2B, TK1, PAICS, GPX1, 
TYMS, DTYMK, DCK, NME2, CAD, RRM2 
BASE EXCISION REPAIR 19 -1.56 0.047 
MPG, TDG, MBD4, LIG3, FEN1, NTHL1, CCNO, XRCC1, POLB, MUTYH, APEX1, LIG1, POLD1, POLD2, OGG1, 
POLD4, POLD3, SMUG1, PCNA 
NUCLEOTIDE EXCISION REPAIR 48 -1.56 0.044 
GTF2H4, TCEA1, RFC5, RAD23B, POLR2A, CDK7, ERCC5, XPA, POLR2B, POLR2D, ERCC4, XAB2, XPC, DDB1, 
CCNH, POLR2J, POLR2F, ERCC3, POLR2L, POLR2C, POLR2G, GTF2H3, ERCC8, POLR2I, POLR2K, RFC3, RFC2, 
ERCC6, ERCC1, LIG1, RPA2, ERCC2, POLD1, POLD2, POLE, POLD4, POLD3, POLR2H, POLR2E, RPA3, GTF2H1, 
MNAT1, RFC4, DDB2, POLE2, RPA1, PCNA, GTF2H2 
KINESINS 24 -1.54 0.034 
KIF3B, KLC1, KIF5B, KIFAP3, KIF26A, KIF2B, KIF9, KIF2A, KIF4B, KLC3, KLC2, KIF4A, KLC4, KIF22, KIF3C, 
KIF5A, KIFC1, KIF2C, KIF18A, KIF11, KIF20A, KIF23, RACGAP1, KIF15 
EXTENSION OF TELOMERES 27 -1.52 0.040 
RFC5, FEN1, DNA2, TERT, NHP2, DKC1, RFC3, RFC2, WRAP53, LIG1, RPA2, POLD1, POLA1, POLD2, POLE, 
POLD4, POLD3, PRIM2, RPA3, RUVBL2, POLA2, RUVBL1, RFC4, POLE2, RPA1, PRIM1, PCNA 
ACTIVATION OF THE PRE 
REPLICATIVE COMPLEX 
30 -1.51 0.033 
RPA4, CDK2, CDC45, DBF4, MCM4, ORC1, CDT1, ORC5, ORC6, RPA2, ORC3, ORC4, POLA1, POLE, MCM5, CDC7, 
PRIM2, MCM10, MCM6, RPA3, CDC6, POLA2, MCM2, MCM7, ORC2, MCM8, POLE2, MCM3, RPA1, PRIM1 
LAGGING STRAND SYNTHESIS 19 -1.51 0.047 
RFC5, FEN1, DNA2, RFC3, RFC2, LIG1, RPA2, POLD1, POLA1, POLD2, POLD4, POLD3, PRIM2, RPA3, POLA2, 
RFC4, RPA1, PRIM1, PCNA 
SYNTHESIS AND 
INTERCONVERSION OF 
NUCLEOTIDE DI AND 
TRIPHOSPHATES 
17 -1.51 0.025 
AK5, GUK1, TXN, GLRX, CMPK1, GSR, TXNRD1, AK1, RRM1, NME1, AK2, NME4, CTPS2, RRM2B, DTYMK, 
NME2, RRM2 
NUCLEOTIDE LIKE PURINERGIC 
RECEPTORS 
16 -1.48 0.043 
GPR17, LPAR4, P2RY11, ADORA2A, P2RY1, P2RY12, P2RY4, LPAR6, ADORA3, ADORA1, P2RY6, P2RY14, 
ADORA2B, P2RY10, P2RY2, P2RY13 
FACTORS INVOLVED IN 
MEGAKARYOCYTE DEVELOPMENT 
AND PLATELET PRODUCTION 
117 -1.46 0.042 
HDAC2, MAFK, IRF1, HIST1H3H, GATA3, MFN1, CDC42, EHD1, IFNA16, RAD51B, RAB5A, IFNA21, H3F3B, 
DOCK1, KIF3B, EP300, MAFG, SIN3A, DOCK6, PRKAR2B, ZFPM2, KLC1, KIF5B, KIFAP3, IFNA5, IFNA10, JMJD1C, 
MAFF, GATA2, RAC1, MFN2, CAPZA2, IFNB1, CAPZA1, ZFPM1, KIF26A, KIF2B, KIF9, KDM1A, PRKACB, IFNA4, 
KIF2A, PRKAR1B, DOCK9, AKAP10, WEE1, CABLES2, PRKACG, GATA5, CDK2, IFNA14, EHD2, H3F3A, GATA1, 
CREBBP, KIF4B, DOCK2, SH2B1, KLC3, ITPK1, IFNA8, GATA6, IFNA2, AK3, IRF7, IFNA6, KLC2, DOCK5, SH2B3, 
HBG2, GATA4, IFNA7, PRKAR2A, HBE1, PRKACA, VPS45, SH2B2, IFNA17, HBB, NFE2, JAK2, PRKAR1A, KIF4A, 
KLC4, IRF3, RCOR1, HMG20B, HBD, KIF22, CBX5, ABL1, KIF3C, HDAC1, KIF5A, DOCK3, CDK5, DOCK8, 
HIST1H3B, CABLES1, KIFC1, KIF2C, MYB, IRF2, AKAP1, HIST1H3E, HIST1H3G, DOCK4, KIF18A, TP53, RAD51C, 
HIST1H3I, KIF11, KIF20A, KIF23, DOCK10, RACGAP1, KIF15 
DARPP 32 EVENTS 24 -1.45 0.043 
PPP2CB, PRKAR2B, PPP3CA, PPP2CA, PDE4C, PPP3R1, PDE4B, PRKACB, PDE4D, PRKAR1B, CALM1, PRKACG, 
CALM2, PPP2R1A, PRKAR2A, PRKACA, PPP1CA, PRKAR1A, CALM3, PPP3CB, PPP1R1B, PPP2R1B, CDK5, 
PPP2R5D 
CYCLIN A B1 ASSOCIATED EVENTS 
DURING G2 M TRANSITION 
15 -1.39 0.048 
CDK7, CDC25B, CCNH, WEE1, PKMYT1, CCNA1, XPO1, MNAT1, CDC25C, CDC25A, CCNA2, PLK1, CCNB1, 
CCNB2, CDK1 
 
 
 
Supplementary Table S7 lncRNAs significantly under- and overexpressed in 
NEAT1 quartile IV versus I.  
 
lncRNA ID CHR. Score(d) Fold Change 
NEAT1 ENSG00000245532 11q13 9.48 1.78 
RP11-439L18.1 ENSG00000232618 6q24 6.89 4.49 
MTUS2-AS1 ENSG00000179141 13q12 4.51 2.05 
NARF-IT1 ENSG00000266236 17q25 4.47 2.24 
AC116366.5 ENSG00000238160 5q31 4.19 1.41 
RP11-574F21.2 ENSG00000228606 1q32 4.14 2.77 
MIR22HG ENSG00000186594 17p13 4.11 2.83 
RP1-90J20.8 ENSG00000224846 6p25 4.10 2.04 
RP11-215P8.3 ENSG00000248559 5q31 3.99 1.88 
RP4-605O3.4 ENSG00000272368 12q13 3.96 1.73 
AC133644.2 ENSG00000280721 2p11 3.76 3.22 
RP11-169E6.1 ENSG00000261173 16q11 3.74 1.61 
C3orf35 ENSG00000198590 3p22 3.73 1.71 
TTLL7-IT1 ENSG00000233061 1p31 3.69 2.63 
RP11-638I2.8 ENSG00000258666 14q32 3.68 1.90 
RP11-421L21.2 ENSG00000235795 1p21 3.60 2.15 
C22orf24 ENSG00000128254 22q12 3.53 2.14 
RP1-45I4.3 ENSG00000227192 6q24 3.52 1.85 
MIR29A ENSG00000226380 7q32 3.52 2.19 
LINC01481 ENSG00000257815 12q15 3.49 1.85 
WI2-85898F10.1 ENSG00000235091 22q13 3.46 3.46 
RP11-253L19.3 ENSG00000255670 12p13 3.45 1.92 
AC127904.2 ENSG00000230732 3q29 3.40 1.95 
RP11-646J21.2 ENSG00000255133 11p13 3.32 1.41 
RP11-203J24.8 ENSG00000227218 9q34 3.31 2.94 
LINC01619 ENSG00000257242 12q21 3.29 3.87 
CTB-131B5.5 ENSG00000254363 5q31 3.29 1.57 
RP11-3D4.3 ENSG00000259408 15q14 3.25 1.40 
RORA-AS1 ENSG00000245534 15q22 -4.57 0.55 
DDX11-AS1 ENSG00000245614 12p11 -4.22 0.50 
  
Supplementary Table S8. Molecular and clinical 
characteristics of 55 MM patients. 
 
Sample Features N/% 
Patients 55 
Median age at diagnosis 67 
Bone damage 60% 
Median BM-PC infiltrate  50% 
del(13) 53% 
del(17) 7% 
t(4;14) 13% 
t(11;14) 20% 
MAF-trx 7% 
HD 31% 
1q gain 49% 
1p loss 11% 
International Staging System (ISS)  
stage I 19 
stage II 19 
stage III 17 
R-ISS  
stage I 12 
stage II 34 
stage III 9 
Median overall survival (OS)  52 months 
Median time to next treatment (TNT)  23 months 
globaltest OS p-value 
PRIMER 5' 0.903 
PRIMER 3' 0.977 
globaltest TNT p-value 
PRIMER 5' 0.655 
PRIMER 3' 0.933 
 
 
 
 
